Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
48.67
-0.15 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
25
26
Next >
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
May 01, 2023
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public...
Via
Benzinga
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront
May 01, 2023
Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA (NASDAQ: SNY) for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently...
Via
Benzinga
Sanofi (SNY) Q1 2023 Earnings Call Transcript
April 28, 2023
SNY earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
April 27, 2023
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in
Via
Benzinga
Earnings Outlook For Sanofi
April 26, 2023
Via
Benzinga
AbbVie Stock Shows Improved Relative Price Strength
April 13, 2023
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see.
Via
Investor's Business Daily
Is Sanofi Stock a Buy Now?
March 25, 2023
The pharma giant has outperformed the broader market over the past 12 months.
Via
The Motley Fool
Earnings Scheduled For April 27, 2023
April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter.
Via
Benzinga
Looking Into Sanofi's Recent Short Interest
March 23, 2023
Via
Benzinga
Why Shares of Regeneron Are Rising Thursday
March 23, 2023
Regeneron released positive phase 3 trial results for its therapy Dupixent.
Via
The Motley Fool
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
April 27, 2023
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher.
Via
Benzinga
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
April 24, 2023
Via
Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
April 21, 2023
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
Via
Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
April 18, 2023
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.
Via
Benzinga
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
April 12, 2023
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...
Via
Benzinga
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
April 11, 2023
Via
Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...
Via
Benzinga
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens
April 10, 2023
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday
Via
Investor's Business Daily
2 Top Healthcare Stocks Defying the Bear Market
April 07, 2023
The market sell-off over the past year hasn't stopped these healthcare giants from rallying.
Via
The Motley Fool
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market
April 06, 2023
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.
Via
The Motley Fool
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
March 30, 2023
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease.
Via
The Motley Fool
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
March 27, 2023
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.
Via
Investor's Business Daily
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
March 25, 2023
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.
Via
The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
March 24, 2023
The major indexes showed volatile, divergent action.
Via
Investor's Business Daily
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
March 24, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met...
Via
Benzinga
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
March 24, 2023
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial...
Via
Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
March 23, 2023
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent.
Via
InvestorPlace
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
March 23, 2023
Bloomberg
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
25
26
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.